Association of SGLT2 inhibitor dapagliflozin with risks of acute kidney injury and all-cause mortality in acute myocardial infarction patients
ConclusionSGLT2 inhibitor DAPA was associated with lower risks of incident AKI and all-cause mortality in AMI patients after PCI therapy. (Source: European Journal of Clinical Pharmacology)
Source: European Journal of Clinical Pharmacology - February 6, 2024 Category: Drugs & Pharmacology Source Type: research
The Effect of Weight Loss Through Lifestyle Interventions in Patients With Heart Failure With Preserved Ejection Fraction —A Systematic Review and Meta-Analysis of Randomised Controlled Trials
Heart failure with preserved ejection fraction (HFpEF) accounts for>50% of heart failure cases and is associated with significant morbidity and health system burden. To date, there have been limited treatment options proven to improve outcomes in these patients, with sodium glucose co-transporter 2 (SGLT2) inhibitors the first class of drug to demonstrate significant clinical benefits, including reductions in heart failure hospitalisation. Obesity is associated with all forms of heart failure and has been linked with worse clinical outcomes. (Source: Heart, Lung and Circulation)
Source: Heart, Lung and Circulation - February 6, 2024 Category: Cardiology Authors: Vivian Y.J. Lee, Lauren Houston, Adam Perkovic, Jennifer Y. Barraclough, Arianne Sweeting, Jie Yu, Robert A. Fletcher, Clare Arnott Tags: Review Source Type: research
Association of SGLT2 inhibitor dapagliflozin with risks of acute kidney injury and all-cause mortality in acute myocardial infarction patients
ConclusionSGLT2 inhibitor DAPA was associated with lower risks of incident AKI and all-cause mortality in AMI patients after PCI therapy. (Source: European Journal of Clinical Pharmacology)
Source: European Journal of Clinical Pharmacology - February 6, 2024 Category: Drugs & Pharmacology Source Type: research
Cardiovascular and mortality outcomes with GLP-1 receptor agonists vs other glucose-lowering drugs in individuals with NAFLD and type 2 diabetes: a large population-based matched cohort study
Conclusions/interpretationIn individuals with NAFLD and type 2 diabetes, GLP-1RAs are associated with lower incidences of adverse CVEs and all-cause mortality compared with metformin or other second- and third-line glucose-lowering medications. However, there was no significant difference in adverse CVEs or all-cause mortality when compared with those taking SGLT2 inhibitors.Graphical Abstract (Source: Diabetologia)
Source: Diabetologia - February 5, 2024 Category: Endocrinology Source Type: research
Diabetic Sarcopenia. A proposed muscle screening protocol in people with diabetes : Expert document
Conclusion: Diabetic sarcopenia has a significant impact on function and quality of life in people with type 2 diabetes mellitus (T2DM), and it is important to give it the same attention as all other traditionally described complications of T2DM. This document aims to establish the foundation for protocolising the screening and diagnosis of diabetic sarcopenia in a manner that is simple and accessible for all levels of healthcare.PMID:38315411 | DOI:10.1007/s11154-023-09871-9 (Source: ENDOCR REV)
Source: ENDOCR REV - February 5, 2024 Category: Endocrinology Authors: Daniel de Luis Rom án Juana Carretero G ómez Jos é Manuel García-Almeida Fernando Garrach ón Vallo German Guzm án Rolo Juan Jos é López Gómez Francisco Jos é Tarazona-Santabalbina Alejandro Sanz-Paris Source Type: research
Diabetic Sarcopenia. A proposed muscle screening protocol in people with diabetes
Conclusion: Diabetic sarcopenia has a significant impact on function and quality of life in people with type 2 diabetes mellitus (T2DM), and it is important to gi ve it the same attention as all other traditionally described complications of T2DM. This document aims to establish the foundation for protocolising the screening and diagnosis of diabetic sarcopenia in a manner that is simple and accessible for all levels of healthcare. (Source: Reviews in Endocrine and Metabolic Disorders)
Source: Reviews in Endocrine and Metabolic Disorders - February 5, 2024 Category: Endocrinology Source Type: research
Comparative Effectiveness of Oral Hypoglycemic Agents for Glycemic Control and Glycemic Variability in Patients with Type 2 Diabetes Mellitus: Using Flash Glucose Monitoring
CONCLUSION: The monotherapy group of SGLT2 inhibitors demonstrated glucose-lowering effects with reduced glycemic variability. Hence, optimum glycemic control is associated with decreased glycemic variability.PMID:38310479 | DOI:10.2174/0115733998267817231227102553 (Source: Current Diabetes Reviews)
Source: Current Diabetes Reviews - February 4, 2024 Category: Endocrinology Authors: Poongothai Venkatachalapathy Karthik Kumar Dos Alagarswamy Mohandoss Murali Munisamy Mohan Sellappan Source Type: research
Diabetic Kidney Disease Without Albuminuria: A New Entity in Diabetic Nephropathy
Iran J Kidney Dis. 2024 Jan;1(1):1-8.ABSTRACTNon-albuminuric diabetic kidney disease (NA-DKD) is characterized by progressive loss of kidney function with an annual loss of estimated glomerular filtration rate (eGFR) more than 3 mL/ min/ 1.73m2 per year. NA-DKD is also associated with the late manifestation of diabetic kidney disease, characterized by reduced eGFR (< 60 mL/min/ 1.73m2), in the absence of albuminuria (urine albumin-to-creatinine ratio [UACR] less than 30 mg/g. The typical glomerular changes seen in diabetic nephropathy are less frequently observed in normoalbuminuric patients, while they predominantly sh...
Source: Iranian Journal of Kidney Diseases - February 3, 2024 Category: Urology & Nephrology Authors: Nooshin Ahmadi Atefeh Amouzegar Source Type: research
